Rheumatoid arthritis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
    • Publication Information:
      Publication: 2004- : London : Elsevier
      Original Publication: London : J. Onwhyn
    • Subject Terms:
      Arthritis, Rheumatoid*/diagnosis ; Arthritis, Rheumatoid*/drug therapy ; Antirheumatic Agents*/therapeutic use ; Rheumatology* ; Janus Kinase Inhibitors*/therapeutic use; Humans ; Glucocorticoids/therapeutic use
    • Abstract:
      Rheumatoid arthritis is a chronic, systemic, autoimmune inflammatory disease that mainly affects the joints and periarticular soft tissues. In this Seminar, we provide an overview of the main aspects of rheumatoid arthritis. Epidemiology and advances in the understanding of rheumatoid arthritis pathogenesis will be reviewed. We will discuss the clinical manifestations of rheumatoid arthritis, classification criteria, and the value of imaging in the diagnosis of the disease. The advent of new medications and the accumulated scientific evidence demand continuous updating regarding the diagnosis and management, including therapy, of rheumatoid arthritis. An increasing number of patients are now able to reach disease remission. This major improvement in the outcome of patients with rheumatoid arthritis has been determined by a combination of different factors (eg, early diagnosis, window of opportunity, treat-to-target strategy, advent of targeted disease-modifying antirheumatic drugs, and combination therapy). We will discuss the updated recommendations of the two most influential societies for rheumatology worldwide (ie, the American College of Rheumatology and European Alliance of Associations for Rheumatology) for the management of rheumatoid arthritis. Furthermore, controversies (ie, the role of glucocorticoids in the management of rheumatoid arthritis and safety profile of Janus kinase inhibitors) and outstanding research questions, including precision medicine approach, prevention, and cure of rheumatoid arthritis will be highlighted.
      Competing Interests: Declaration of interests PE has received grants from Lilly and Samsung; consulting fees from BMS, Boehringer-Ingelheim, Lilly, and Novartis; payment and honoraria from Galapagos, Lilly, and Novartis; support for attending meetings or travel from Lilly; and has participated on a data safety monitoring board or advisory board with AstraZeneca. All other authors declare no competing interests.
      (Copyright © 2023 Elsevier Ltd. All rights reserved.)
    • Accession Number:
      0 (Antirheumatic Agents)
      0 (Glucocorticoids)
      0 (Janus Kinase Inhibitors)
    • Publication Date:
      Date Created: 20240119 Date Completed: 20240122 Latest Revision: 20240207
    • Publication Date:
      20240207
    • Accession Number:
      10.1016/S0140-6736(23)01525-8
    • Accession Number:
      38240831